The monitoring board did not specify potential harms in its Dec. 22 statement, though high doses of anticoagulants are associated with increased bleeding, including in the gastrointestinal tract and inside the skull. Full-dose blood thinners have not reduced the need for organ support among critically ill patients, indicating the treatment offers no benefit.
The trial’s leaders are now urgently trying to reach hospitals who may still be administering high-dose blood thinners to critical patients in belief that the risks outweigh benefits, according to the NYT.
Currently, the trial will continue only for hospitalized patients who are moderately ill, meaning they are not in intensive care, not on ventilators or at risk of organ failure. The trials leaders will continue monitoring data to determine whether severe patients can be enrolled again.
To read more about the trial, click here.
More articles on patient safety and outcomes:
Pandemic may be triggering more severe migraines, experts say
Why healthcare leaders should stop overlooking nutrition in the quest for better outcomes: 4 insights
COVID-19 viral load may predict patient outcomes, study suggests
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
